GlassScriptPhysician profile
Gena Byrd-Turner
NPI 1932775632
$2,424.54
in general payments reported to CMS, 2019-2025
31 companies · $822 in 2025
The $822 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $789 · 2022: $542 · 2023: $255 · 2024: $17.86 · 2025: $822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,094.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,094.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $271.39 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $231.33 | 2025 | Tezspire, Airsupra |
| Jazz Pharmaceuticals INC. | $220.49 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $164.43 | 2021-2025 | |
| Medical Device Business Services, INC. | $151.24 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $123.30 | 2022 | |
| Amneal Pharmaceuticals LLC | $121.41 | 2021 | |
| Insightec,INC | $110.46 | 2023 | Exablate |
| Takeda Pharmaceuticals U.S.A., INC. | $97.88 | 2025 | Cuvitru |
| Biogen, INC. | $89.50 | 2021-2022 | |
| Ars Pharmaceuticals Operations, INC. | $84.21 | 2025 | Neffy |
| Regeneron Healthcare Solutions, INC. | $83.60 | 2025 | Dupixent |
| Csl Behring | $65.80 | 2025 | Andembry, Haegarda |
| Glaxosmithkline, LLC. | $61.92 | 2025 | Trelegy Ellipta, Nucala |
| Supernus Pharmaceuticals, INC. | $58.55 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $56.77 | 2025 | Tezspire |
| Allergan, INC. | $48.04 | 2021-2022 | |
| Impel Pharmaceuticals INC. | $46.47 | 2022-2023 | Trudhesa |
| Ethicon US, LLC | $42.54 | 2022 | |
| Merz Pharmaceuticals, LLC | $37.93 | 2021 | |
| Harmony Biosciences LLC | $37.09 | 2022 | |
| Lundbeck LLC | $33.00 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $32.23 | 2021 | |
| Grifols USA, LLC | $26.73 | 2025 | Xembify |
| Lilly USA, LLC | $23.36 | 2021 | |
| Biocryst US Sales Co., LLC | $21.64 | 2025 | Orladeyo |
| Argenx US, INC. | $20.69 | 2023 | Vyvgart Hytrulo |
| Eisai INC. | $17.86 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.84 | 2022 | |
| Upsher-Smith Laboratories LLC | $15.62 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $13.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gena Byrd-Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.